UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
____________________
FORM
8K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
____________________
Date
of
Report
March
30, 2006
_______________________
Nanobac
Pharmaceuticals, Incorporated
(Exact
name of registrant as specified in its charter)
|
Florida
|
0-24696
|
59-3248917
|
|
(State
or Other
Jurisdiction
|
(Commission
File
|
(I.R.S.
Employer
|
|
of
Incorporation)
|
Number)
|
Identification
Number)
|
4730
N. Habana Avenue, Tampa, Florida 33614
(Address
of Principal Executive Office) (Zip Code)
(813)
264-2241
(Registrant’s
telephone number, including area code)
Item
5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
Nanobac
announces the following changes in its Board of Directors
New
Director
Dr.
Benedict S. Maniscalco, M.D. - Director of Clinical Research, Medical Director
and member of the Board of Directors - Dr.
Maniscalco joined the Board of Directors on March 29, 2006.
2001
to
present Dr. Maniscalco has been in the private practice of cardiology. He was
with Tampa Heart Center in Tampa Florida in 2000 to 2001. Dr. Maniscalco was
in
private practice for consultive cardiology with Health Centers of Excellence,
Inc. as Chief Executive Officer in Tampa Florida from March 1998 thorough
January 2000. From 1976 through 1998, he was an officer and board member of
a
large multi specialty cardiovascular group practice. From 1979 through 1996
he
was co-founder of St. Joseph’s Heart Institute in Tampa, Florida and served as
Director of Cardiac Catheterization and Director of Cardiology during his
tenure.
Over
past
30 years, Dr. Maniscalco has been a member of numerous local, state and national
professional societies. He has served as President and Governor of the Florida
Chapter of the American College of Cardiology and has been involved in numerous
committees dealing with socioeconomic and medical policies in both the American
College of Cardiology and the Society for Cardiac Angiography and Interventions.
He has been a frequent lecturer at the local, state and national level, on
both
clinical and non-clinical matters affecting the delivery of cardiovascular
services.
Dr.
Maniscalco received his medical degree from the Duke University School of
Medicine in 1967. He interned at Grady Memorial Hospital in Atlanta and did
his
junior and senior residencies at Emory University Affiliated Hospitals, followed
by a fellowship in Cardiovascular diseases from 1973-1975. He is licensed to
practice in both Florida and Georgia and is certified by the American Board
of
Internal Medicine and the American Sub-Specialty Board in Cardiovascular
disease.
Director
Resignation
Dr.
Maniscalco replaces Dr. Jan Egberts who has resigned from Nanobac
Pharmaceuticals, Incorporated effective March 29, 2006 due to time constraints
associated with his other business and personal interests. Dr. Egberts did
not
have disagreements with the Registrant.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
|
|
| |
Nanobac Pharmaceuticals,
Incorporated |
| |
(Registrant) |
| |
|
|
|
|
| Date: March
30, 2006 |
By: |
/s/
John D.
Stanton
|
| |
John
D. Stanton, Chief Executive
Officer
|